ERBB2 and cancer: Consistent with the requirement of Nek2 for the survival of mutp53 cancer cells, we were able to generate H/+;ErbB2/Nek2−/−, but not H/−;ErbB2/Nek2−/− cell lines by CRISPR/Cas9 technology.